22
220100.KQ FutureChem Co.Ltd
- Market cap
- KRW 195B
- P/E
- -
- P/B
- 3.55x
- ROE
- 0.9%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 220100.KQ undervalued?
Graham numberThe Graham number of FutureChem Co.Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
FutureChem Co.Ltd fundamental analysis
6 of 22 checks passedROE 0/2
Low return on equity (0.9%), below 10%.
ROA 0/1
Return on assets (0.7%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-12.7%) is below the industry median (1.8%).
Revenue Growth 2/2
Revenue grew 14.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (3.8%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is 1.6x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (3.5x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
FutureChem Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products in pipeline include [18F]FC303, [177Lu]FC705, and 225Ac for the treatment of pros…
Full company profileFutureChem Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
FutureChem Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.63B | 3.00B | 5.64B | 8.17B | 11.0B | 11.8B | 12.6B | 14.0B | 17.3B | 18.7B | 21.3B |
| Gross Profit | -1.33B | -483M | -1.51B | 513M | 2.84B | 2.50B | 1.71B | 1.57B | 3.02B | 4.30B | 5.68B |
| Operating Income | -3.88B | -4.53B | -12.1B | -5.50B | -4.89B | -7.90B | -12.9B | -8.41B | -9.47B | -7.75B | -10.9B |
| EBITDA | - | - | - | - | - | - | -8.04B | -566M | -2.61B | -4.87B | 6.20B |
| Net Income | -27.3B | -4.49B | -12.0B | -5.37B | -23.1B | -3.42B | -14.0B | -6.71B | -9.42B | -11.3B | 502M |
| EPS | -3,324 | -547 | -1,426 | -640 | -1,697 | -177 | -632 | -304 | -426 | -480 | 21 |
| Balance Sheet | |||||||||||
| Total Assets | 33.1B | 36.0B | 64.0B | 63.2B | 82.5B | 77.1B | 88.7B | 72.8B | 74.4B | 74.5B | 68.4B |
| Total Liabilities | 1.58B | 8.80B | 47.6B | 52.1B | 39.1B | 24.4B | 18.6B | 8.92B | 20.0B | 19.7B | 13.3B |
| Shareholders' Equity | 31.5B | 27.2B | 16.5B | 11.2B | 43.4B | 52.7B | 70.1B | 63.8B | 54.4B | 54.7B | 54.9B |
| Cash & Short-term Investments | 23.4B | 11.2B | 38.3B | 28.3B | 46.8B | 32.6B | 40.7B | 25.8B | 33.4B | 4.34B | 5.77B |
| Total Debt | - | - | - | 14.9B | 15.6B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.20B | -2.84B | -3.34B | -2.71B | -2.28B | -2.95B | -7.61B | -3.72B | -3.21B | -2.43B | -5.64B |
| Capital Expenditure | 796M | 6.05B | 8.34B | 6.93B | 3.44B | 8.39B | 2.99B | 2.42B | 1.88B | 8.53B | 3.60B |
| Free Cash Flow | - | - | - | - | -5.78B | -12.9B | -11.6B | -8.44B | -5.09B | -11.0B | -9.25B |
| Ratios | |||||||||||
| ROE | -86.5% | -16.5% | -72.7% | -48.1% | -53.3% | -6.5% | -19.9% | -10.5% | -17.3% | -20.6% | 0.9% |
| ROA | -82.4% | -12.5% | -18.7% | -8.5% | -28.0% | -4.4% | -15.7% | -9.2% | -12.7% | -15.1% | 0.7% |
| Net Profit Margin | -1,678.8% | -149.8% | -212.4% | -65.7% | -209.8% | -28.9% | -111.0% | -48.0% | -54.5% | -60.3% | 2.4% |
| Debt to Equity | - | - | - | 1.34x | 0.36x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
FutureChem Co.Ltd dividends
FutureChem Co.Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1.2:1 on Sep 17, 2026.
Who owns FutureChem Co.Ltd
- Insiders 11.55%
- Institutions 0.19%
- Public & others 88.26%
- Shares outstanding 28.1M
- Free float 23.1M
FutureChem Co.Ltd company profile
- Company name
- FutureChem Co.Ltd
- Ticker
- 220100.KQ
- ISIN
- KR7220100002
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 72
- Fiscal year end
- December
- Address
- PyeongHwa Building, Seoul, South Korea, 04794
- Phone
- 82 2 497 3114
- Website
- futurechem.co.kr
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products in pipeline include [18F]FC303, [177Lu]FC705, and 225Ac for the treatment of prostate cancer; F-FMT for brain tumor diagnosis; FC-505 for the treatment of arteriosclerosis and myocardial infarction; FC-211 for Alzheimer's disease; FC-2 for the treatment of hypoxia; FC-3 for solid cancer; FC801 for bladder cancer; and FC901 for the treatment of pulmonary fibrosis. The company also provides automatic synthesis equipment, such as sCUBE-RXN (synthetic), sCUBE-P&F (tablet-formulation), and sCUBE-M (radioactive, metal). In addition, it offers molecular imaging device airway sleeve and disposable cartridges, as well as engages in medical device wholesale and healthcare business. FutureChem Co.,Ltd was founded in 1999 and is headquartered in Seoul, South Korea.
FutureChem Co.Ltd management
2- Mr. Dae-Yoon ChiChairman of The Board and Chief Executive Officer · born 1955
- Heeseop GilExecutive Director